AI Robotics in Medicine

Simply Wall Street’s AI Healthcare screener spotlights ASO International, eWeLLLtd, and FINDEX—Japan-focused plays in orthodontics, home nursing, and hospital software—trading below one fair‑value estimate (ASO 32. 8% under; FINDEX 39.

4% under) alongside solid metrics (ASO 12. 3% net margin; FINDEX 22.

4% five‑year earnings growth, 20. 2% net margin, 22.

3% ROE; eWeLLLtd ~20% annual revenue/earnings growth and ROE >30%).

The through-line is a value‑versus‑governance tradeoff: despite supportive shareholder signals (eWeLLLtd buybacks and higher dividend guidance; FINDEX guiding profit and dividend stability into 2026), the screen flags board independence gaps and higher‑risk external funding—ASO has zero independent directors and heavy external borrowing; eWeLLLtd and FINDEX rely entirely on higher‑risk external funding with limited board independence.

Watch whether these capital‑return moves and execution in AI‑enabled offerings can offset governance and funding risks to close the valuation gaps.

Tracking: Medicine Robotics · AI Medicine · AI Healthcare

1. Screen Flags Three Undervalued Japanese AI Healthcare Stocks

Simply Wall Street’s Transformative AI Healthcare Stocks screener highlights ASO International, eWeLLLtd, and FINDEX as Japan-focused plays blending AI with dentistry, home nursing, and hospital software.

ASO, which offers AI-assisted orthodontic tools and 3D printing, trades 32. 8% below one fair-value estimate and posts a 12.

3% net margin. FINDEX, whose portfolio includes EMR systems and generative AI tools, trades 39.

4% under one estimate with five-year earnings growth of 22. 4%, a 20.

2% net margin, and 22. 3% ROE.

eWeLLLtd, a cloud platform central to home-based care workflows, is expected to grow revenue and earnings about 20% annually, with ROE above 30%, and trades below one estimate of future cash flow value.

But the screen flags governance and funding risks: ASO has zero independent directors and heavy external borrowing; eWeLLLtd and FINDEX rely entirely on higher-risk external funding with limited board independence.

eWeLLLtd’s recent buybacks and higher dividend guidance, and FINDEX’s guidance for profit and dividend stability into 2026, round out the picture.

Key facts:

- ASO International trades 32.8% below one fair-value estimate.

- ASO International net margin: 12.3%.

- eWeLLLtd revenue and earnings expected to grow about 20% annually.

- eWeLLLtd ROE above 30%; trades below one cash flow value estimate.

- FINDEX trades 39.4% under one fair-value estimate.

Why it matters: AI is being applied to essential healthcare services in Japan—from orthodontics to home nursing and hospital IT—supported by pressure to control costs and expand access.

If growth and profitability hold, the discounts to one set of fair-value estimates could represent mispricing for investors seeking AI-in-healthcare exposure.

However, concentrated reliance on external borrowing and weak board independence elevate governance and financing risk.

Watch for changes to funding mix, any moves to strengthen boards, eWeLLLtd’s execution toward ~20% growth, and FINDEX’s delivery on profit and dividend stability into 2026.

Simplywall